These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 16818289

  • 1. The relationship between transferrin saturation and erythropoiesis during stem cell transplantation.
    Altes A, Remacha AF, Sarda P, Baiget M, Canals C, Sierra J.
    Haematologica; 2006 Jul; 91(7):992-3. PubMed ID: 16818289
    [Abstract] [Full Text] [Related]

  • 2. Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation.
    Kanda J, Mizumoto C, Kawabata H, Tsuchida H, Tomosugi N, Matsuo K, Uchiyama T.
    Haematologica; 2008 Oct; 93(10):1550-4. PubMed ID: 18641032
    [Abstract] [Full Text] [Related]

  • 3. Effect of repeated apotransferrin administrations on serum iron parameters in patients undergoing myeloablative conditioning and allogeneic stem cell transplantation.
    Parkkinen J, Sahlstedt L, von Bonsdorff L, Salo H, Ebeling F, Ruutu T.
    Br J Haematol; 2006 Oct; 135(2):228-34. PubMed ID: 16925790
    [Abstract] [Full Text] [Related]

  • 4. Non-transferrin-bound iron in haematological patients during chemotherapy and conditioning for autologous stem cell transplantation.
    Sahlstedt L, von Bonsdorff L, Ebeling F, Parkkinen J, Juvonen E, Ruutu T.
    Eur J Haematol; 2009 Nov; 83(5):455-9. PubMed ID: 19572995
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Biochemical indices for the assessment of nutritional status during hematopoietic stem cell transplantation: are they worth using? A single center experience.
    Rzepecki P, Barzal J, Sarosiek T, Szczylik C.
    Bone Marrow Transplant; 2007 Sep; 40(6):567-72. PubMed ID: 17637693
    [Abstract] [Full Text] [Related]

  • 8. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation.
    Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, Raad II, Manning JT, Han X.
    Cancer; 2007 Sep 15; 110(6):1303-6. PubMed ID: 17614303
    [Abstract] [Full Text] [Related]

  • 9. Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse.
    Yakoub-Agha I, Saule P, Magro L, Cracco P, Duhamel A, Coiteux V, Bruno B, Dufossé F, Jouet JP, Dessaint JP, Labalette M.
    Biol Blood Marrow Transplant; 2009 Apr 15; 15(4):496-504. PubMed ID: 19285638
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation.
    Armistead PM, Mohseni M, Gerwin R, Walsh EC, Iravani M, Chahardouli B, Rostami S, Zhang W, Neuberg D, Rioux J, Ghavamzadeh A, Ritz J, Antin JH, Wu CJ.
    Exp Hematol; 2008 Sep 15; 36(9):1205-15. PubMed ID: 18550258
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
    Patriarca F, Bacigalupo A, Sperotto A, Isola M, Soldano F, Bruno B, van Lint MT, Iori AP, Santarone S, Porretto F, Pioltelli P, Visani G, Iacopino P, Fanin R, Bosi A, GITMO.
    Haematologica; 2008 Oct 15; 93(10):1514-22. PubMed ID: 18728030
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May 15; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 18. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.
    Yoon DH, Sohn BS, Jang G, Kim EK, Kang BW, Kim C, Kim JE, Kim S, Lee DH, Lee JS, Park SJ, Park CJ, Huh J, Suh C.
    Transfusion; 2009 Sep 15; 49(9):1890-900. PubMed ID: 19453991
    [Abstract] [Full Text] [Related]

  • 19. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
    Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Chen HY, Mahmud N, Quigley J, Hoffman R, Jessop E, Beri R, Rondelli D.
    Bone Marrow Transplant; 2006 Oct 15; 38(7):477-82. PubMed ID: 16980995
    [Abstract] [Full Text] [Related]

  • 20. Kinetics of recovery of dendritic cell subsets after reduced-intensity conditioning allogeneic stem cell transplantation and clinical outcome.
    Talarn C, Urbano-Ispizua A, Martino R, Pérez-Simón JA, Batlle M, Herrera C, Granell M, Gaya A, Torrebadell M, Fernández-Avilés F, Aymerich M, Marín P, Sierra J, Montserrat E.
    Haematologica; 2007 Dec 15; 92(12):1655-63. PubMed ID: 18055989
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.